List of Cuvrior drug patents

Cuvrior is owned by Orphalan.

Cuvrior contains Trientine Tetrahydrochloride.

Cuvrior has a total of 2 drug patents out of which 0 drug patents have expired.

Cuvrior was authorised for market use on 28 April, 2022.

Cuvrior is available in tablet;oral dosage forms.

Cuvrior can be used as a method for the treatment of adult patients with stable wilson’s disease who are de-coppered and tolerant to penicillamine.

The generics of Cuvrior are possible to be released after 03 May, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10988436 ORPHALAN Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
May, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11072577 ORPHALAN Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
May, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 28, 2025
Orphan Drug Exclusivity (ODE) Apr 28, 2029

Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient

Market Authorisation Date: 28 April, 2022

Treatment: A method for the treatment of adult patients with stable wilson’s disease who are de-coppered and tolerant to penicillamine

Dosage: TABLET;ORAL

More Information on Dosage

CUVRIOR family patents

4

United States

3

European Union

2

China

1

Germany

1

Singapore

1

Brazil

1

Japan

1

Argentina

1

Colombia

1

Morocco

EA

1

EA

1

Canada

1

Spain

1

Australia

1

Korea, Republic of

1

Taiwan, Province of China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in